---
title: 'Three-month life expectancy as inclusion criterion for clinical trials in
  advanced pancreatic cancer: is it really a valid tool for patient selection?'
date: '2023-10-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37794220/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231005180843&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Despite the definition of a life expectancy of > 3 months
  as a standard inclusion criterion in clinical trials for advanced PC, a significant
  proportion of study patients does not survive > 3 ...'
disable_comments: true
---
CONCLUSIONS: Despite the definition of a life expectancy of > 3 months as a standard inclusion criterion in clinical trials for advanced PC, a significant proportion of study patients does not survive > 3 ...